

**PRESS RELEASE**  
**2011 first-quarter net sales**

Villepinte, 27 April 2011

**Consolidated Group revenue (IFRS):**

In thousands of euros	2011	2010	Change
<b>Total first quarter .....</b>	<b>95,053</b>	<b>86,684</b>	<b>+9.7%</b>

**Consolidated revenue by region:**

In thousands of euros	2011	2010	Change
European subsidiaries	68,118	65,974	+3.2%
Other markets	26,936	20,709	+30.1%
<b>Total.....</b>	<b>95,053</b>	<b>86,684</b>	<b>+ 9.7%</b>

**First quarter revenue up 9.7%**

Sales in Europe rose 3.2% driven by gains from Dotarem.

Other markets grew 30.1%, increasing their share in total Group revenue to 28%, up from 24% in 2010. In the US, the resumption of direct distribution of Lipiodol (Ethiodol) provided a strong and exceptional boost to first-quarter sales. In the rest of the world, both Dotarem and Xenetix showed strong growth.

Dotarem sales were up 19.7% on gains of 17.6% in Europe and 31.9% for other regions.

Xenetix sales increased 5.4% that included a 2.6% decline in Europe and 29.6% growth in other regions.

**Contact:** Finance and Administration Department Tel. 01 45 91 50 69